Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α
Authors: Morris Sherman, George Marinos, Farhad Sedarati
Journal: Annals of Internal Medicine (2001)

Letters20 November 2001Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-αMorris Sherman, MD, George Marinos, MD, and Farhad Sedarati, PhDMorris Sherman, MDToronto General Hospital; Toronto, Ontario M5G 2C4, Canada (Sherman)Prince of Wales Hospital; NSW 2031 Sydney, Australia (Marinos)Hoffmann-La Roche; Nutley, NJ 07110 (Sedarati)Search for more papers by this author, George Marinos, MDToronto General Hospital; Toronto, Ontario M5G 2C4, Canada (Sherman)Prince of Wales Hospital; NSW 2031 Sydney, Australia (Marinos)Hoffmann-La Roche; Nutley, NJ 07110 (Sedarati)Search for more papers by this author, and Farhad Sedarati, PhDToronto General Hospital; Toronto, Ontario M5G 2C4, Canada (Sherman)Prince of Wales Hospital; NSW 2031 Sydney, Australia (Marinos)Hoffmann-La Roche; Nutley, NJ 07110 (Sedarati)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-10-200111200-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Zylberberg and colleagues (1) and others (2) have reported that patients infected with hepatitis C virus (HCV) genotype 4 respond poorly to interferon-α. We recently documented similar findings (3). However, we observed marked improvement in initial and sustained virologic response during and after treatment with peginterferon-α2a (40 kDa) (PEGASYS [Hoffmann-La Roche, Nutley, New Jersey]) compared with unmodified interferon-α therapy.Sixteen of 1130 patients participating in three multicenter trials had HCV genotype 4 infection. Five patients were treated with unmodified interferon-α (3 mIU three times weekly for 48 weeks [n = 2] or 6 mIU three times weekly ...References1. Zylberberg H, Chaix ML, Bréchot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α [Letter]. Ann Intern Med. 2000;132:845-6. [PMID: 10819720] LinkGoogle Scholar2. Marie-Laure C, et al . Genotype 4 HCV infection is associated with a poor response to α-interferon: results of a matched study [Abstract]. Hepatology. 1999;4:589A. Google Scholar3. Sherman M, Dusheiko G, Haussinger D, Marcellin P, Marinos G, Munoz-Espinoza L, et al . Superior virologic response in genotype 4 chronic hepatitis C patients treated with pegylated (40kd) interferon alfa 2A compared to standard interferon [Abstract]. Hepatology. 2000;32:348A. MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Toronto General Hospital; Toronto, Ontario M5G 2C4, Canada (Sherman)Prince of Wales Hospital; NSW 2031 Sydney, Australia (Marinos)Hoffmann-La Roche; Nutley, NJ 07110 (Sedarati)Grant Support: By a research grant from F. Hoffman-La Roche, Ltd., Basel, Switzerland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInfection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α Hervé Zylberberg , M. L. Chaix , and Christian Bréchot Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and Ribavirin Moises Diago , Tarek Hassanein , Juan Rodés , Andrew M. Ackrill , and Farhad Sedarati Metrics Cited BySafety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4Hepatitis crónica por virus de la hepatitis C genotipo 4Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Clinical and Pathological Characteristics and Response to Combination Therapy of Genotype 4 Chronic Hepatitis C Patients: Experience from a Spanish CenterManagement of hepatitis C virus genotype 4Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and RibavirinMoises Diago, MD, Tarek Hassanein, MD, Juan Rodés, MD, Andrew M. Ackrill, PhD, and Farhad Sedarati, PhDSlow viral dynamics of hepatitis C virus genotype 4Effects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis CDevelopments in the treatment of chronic hepatitis C 20 November 2001Volume 135, Issue 10Page: 927-928KeywordsClinical trialsDiagnostic techniquesFibrosisHepatitis AHepatitis C virusInfectious hepatitisPatientsRNAResearch grantsViral load ePublished: 20 November 2001 Issue Published: 20 November 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...